GRTS - グリットスト―ン・オンコロジ― （Gritstone Oncology Inc.） グリットスト―ン・オンコロジ―GRTSのチャート
GRTSの企業情報
| symbol | GRTS |
|---|---|
| 会社名 | Gritstone Oncology Inc （グリットスト―ン・オンコロジ―） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Gritstone Oncology Inc. is an immuno-oncology company that develops tumor-specific cancer immunotherapies to fight multiple cancer types. The Company focuses to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop treatments for lung cancer. It provides Gritstone EDGE which is a tumor-specific neo-antigen (TSNA) prediction platform that predicts the presence of a patient’s TSNA on tumor cells. It also develops and manufactures a patient-specific therapeutic to direct a robust thymus (T) cell response to those TSNA predicted to be presented on the patient’s tumor. In its GRANITE-001 product candidate each of the viral prime and RNA boost immunizations contain a patient-specific set of predicted TSNA and the viral prime and RNA boost in its SLATE product candidate series contains a fixed TSNA cassette that is designed for the subset of patients with tumor neoantigens. グリットスト―ン・オンコロジ―は米国の新薬開発企業。AI技術を利用したがん治療のパイプラインを開発。各患者の腫瘍の個々の性質に焦点を当て、同社のAIプラットフォ―ムGritstone EDGEの予測能力を組み合わせることにより、複数のタイプのがんと闘う患者向けに個人化免疫療法を開発、提供する。本社所在地はカリフォルニア州エメリ―ビル。 Gritstone Oncology, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars-first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient's immune system to specifically attack and destroy disease-causing cells. The company's lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an 'off-the-shelf' shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. The company also has a bispecific antibody (BiSAb) program for solid tumors in lead optimization. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, as well as a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. |
| 本社所在地 | 5858 Horton Street Suite 210 Emeryville CA 94608 USA |
| 代表者氏名 | Andrew R. Allen アンドリュー・R・アレン |
| 代表者役職名 | President Chief Executive Officer Co-Founder Director |
| 電話番号 | +1 510-871-6100 |
| 設立年月日 | 42217 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 100人 |
| url | www.gritstoneoncology.com |
| nasdaq_url | https://www.nasdaq.com/symbol/grts |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -53.00400 |
| 終値（lastsale） | 11.88 |
| 時価総額（marketcap） | 0 |
| 時価総額 | 時価総額（百万ドル） 423.78200 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 535.66500 |
| 当期純利益 | 当期純利益（百万ドル） -55.66800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Gritstone Oncology Inc revenues was not reported. Net loss increased 98% to $28.8M. Higher net loss reflects Research and development - Bala increase from $11.5M to $23.5M (expense) General and administrative - increase of 57% to $4.3M (expense) Stock-based Compensation in SGA increase from $111K to $578K (expense). |
GRTSのテクニカル分析
GRTSのニュース
Gritstone bio Inc. (NASDAQ:GRTS) Shares Are Up 53.28% From The Lows, But Can They Stay Up? 2022/09/03 14:30:00 Marketing Sentinel
In last trading session, Gritstone bio Inc. (NASDAQ:GRTS) saw 0.88 million shares changing hands with its beta currently measuring 0.53. Company’s recent per share price level of $3.66 trading at $0.24 or 7.02% at ring of the bell on the day assigns it a market valuation of $268.75M. That closing price of GRTS’s stock is … Gritstone bio Inc. (NASDAQ:GRTS) Shares Are Up 53.28% From The Lows, But Can They Stay Up? Read More »
Gritstone to Participate in Two Upcoming Investor Conferences 2022/09/01 20:05:00 GlobeNewswire
EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that management will present at the 2022 Wells Fargo Healthcare Conference, taking place September 7-9, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright 24 th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY. The events will also be available via webcast. Please find additional details about the events below.
Gritstone Oncology''s Return On Capital Employed Overview 2022/08/24 14:00:41 Benzinga
Benzinga Pro data, Gritstone Oncology (NASDAQ: GRTS ) reported Q2 sales of $5.47 million. Earnings fell to a loss of $29.52 million, resulting in a 2.07% decrease from last quarter. In Q1, Gritstone Oncology brought in $7.19 million in sales but lost $28.92 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com
GRTS stock slips as Goldman cuts to sell on liquidity issues (NASDAQ:GRTS) 2022/08/22 13:00:43 Seeking Alpha
Gritstone bio (GRTS) slipped ~14% in the pre-market trading Monday after Goldman Sachs downgraded the immunotherapy developer to Sell from Neutral, citing concerns over its…
Goldman Sachs Downgrades Gritstone Oncology to Sell 2022/08/22 06:05:04 Investing.com
https://www.investing.com/news/pro/goldman-sachs-downgrades-gritstone-oncology-to-sell-432SI-2877077
Gritstone bio Inc. (NASDAQ:GRTS) Shares Are Up 53.28% From The Lows, But Can They Stay Up? 2022/09/03 14:30:00 Marketing Sentinel
In last trading session, Gritstone bio Inc. (NASDAQ:GRTS) saw 0.88 million shares changing hands with its beta currently measuring 0.53. Company’s recent per share price level of $3.66 trading at $0.24 or 7.02% at ring of the bell on the day assigns it a market valuation of $268.75M. That closing price of GRTS’s stock is … Gritstone bio Inc. (NASDAQ:GRTS) Shares Are Up 53.28% From The Lows, But Can They Stay Up? Read More »
Gritstone to Participate in Two Upcoming Investor Conferences 2022/09/01 20:05:00 GlobeNewswire
EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that management will present at the 2022 Wells Fargo Healthcare Conference, taking place September 7-9, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright 24 th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY. The events will also be available via webcast. Please find additional details about the events below.
Gritstone Oncology''s Return On Capital Employed Overview 2022/08/24 14:00:41 Benzinga
Benzinga Pro data, Gritstone Oncology (NASDAQ: GRTS ) reported Q2 sales of $5.47 million. Earnings fell to a loss of $29.52 million, resulting in a 2.07% decrease from last quarter. In Q1, Gritstone Oncology brought in $7.19 million in sales but lost $28.92 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com
GRTS stock slips as Goldman cuts to sell on liquidity issues (NASDAQ:GRTS) 2022/08/22 13:00:43 Seeking Alpha
Gritstone bio (GRTS) slipped ~14% in the pre-market trading Monday after Goldman Sachs downgraded the immunotherapy developer to Sell from Neutral, citing concerns over its…
Goldman Sachs Downgrades Gritstone Oncology to Sell 2022/08/22 06:05:04 Investing.com
https://www.investing.com/news/pro/goldman-sachs-downgrades-gritstone-oncology-to-sell-432SI-2877077
Gritstone bio and CEPI Expand Vaccine Agreement to Tackle Omicron Variant 2021/12/06 12:00:00 Intrado Digital Media
EMERYVILLE, Calif. and OSLO, Norway, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of their agreement in order to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstones Omicron vaccine candidate in South Africa, where a CEPI-funded clinical trial of Gritstones Beta variant COVID-19 vaccine is due to begin shortly. The SARS-CoV-2 T cell epitopes (TCEs) administered within Gritstones SAM COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platforms potential to address both Omicron and future variants of concern.
Erin Jones Sells 1,000 Shares of Gritstone bio, Inc. (NASDAQ:GRTS) Stock 2021/12/05 11:42:42 Dakota Financial News
Gritstone bio, Inc. (NASDAQ:GRTS) COO Erin Jones sold 1,000 shares of the businesss stock in a transaction that occurred on Wednesday, December 1st. The shares were sold at an average price of $13.01, for a total transaction of $13,010.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through []
Gritstone bio (NASDAQ:GRTS) Sees Unusually-High Trading Volume 2021/12/03 08:40:44 ETF Daily News
Gritstone bio, Inc. (NASDAQ:GRTS) shares saw unusually-high trading volume on Wednesday . Approximately 37,656 shares changed hands during trading, a decline of 98% from the previous sessions volume of 1,521,021 shares.The stock last traded at $13.34 and had previously closed at $13.20. GRTS has been the subject of several recent research reports. Zacks Investment Research [] The post Gritstone bio (NASDAQ:GRTS) Sees Unusually-High Trading Volume appeared first on ETF Daily News .
Gritstone extends rally after dismissing impact of Omicron on its COVID-19 vaccines 2021/11/30 22:03:16 Seeking Alpha
Are Investors Declined To Sell Their Gritstone bio Inc. (NASDAQ: GRTS) Holdings? 2021/11/30 14:00:00 Stocks Register
Gritstone bio Inc. (NASDAQ:GRTS) traded at $10.50 at close of the session on Monday, 11/29/21, made a downward move of -5.58% on its previous day’s price. Looking at the stock we see that its previous close was $11.12 and the beta (5Y monthly) reads 0.11 with the day’s price range being $10.3481 – $11.40. In … Are Investors Declined To Sell Their Gritstone bio Inc. (NASDAQ: GRTS) Holdings? Read More »